Amycretin and tirzepatide aren’t really competitors yet, because only one of them is available. Tirzepatide (sold as Zepbound and Mounjaro) is FDA approved, on the market, and the most effective weight loss medication currently available. Amycretin is Novo Nordisk’s investigational next-generation drug, still in trials, that aims for strong results and adds a pill option. They work through different hormone combinations, and amycretin is years from any approval. If you’re weighing them, the practical takeaway is simple: tirzepatide works now, while amycretin is a future possibility.<\/p>\n
Tirzepatide is a once-weekly injection that activates two hormone receptors, GLP-1 and GIP. It’s sold as Zepbound (for weight loss) and Mounjaro (for type 2 diabetes), and it’s currently the most effective approved obesity medication. In its main obesity trial (SURMOUNT-1), tirzepatide produced about 21% to 22.5% average weight loss at the highest dose over roughly 72 weeks. In a head-to-head trial against semaglutide (SURMOUNT-5), tirzepatide came out ahead. Beyond weight, it has proven benefits in obesity-related conditions, including heart failure with preserved ejection fraction in people with obesity. The key point: tirzepatide is available now<\/a>, with a large, mature evidence base.<\/p>\n Amycretin is Novo Nordisk’s investigational next-generation drug. It activates GLP-1 (the same pathway tirzepatide uses, in part) plus amylin (a fullness hormone), all in a single molecule, and it’s being developed as both a weekly injection and a daily pill.<\/p>\n Early results are promising: injectable amycretin produced estimated weight loss of about 22% at 36 weeks in an early obesity study, and a November 2025 Phase 2 trial in people with type 2 diabetes showed up to about 14.5% with the injection and 10.1% with the pill. Both forms are entering Phase 3 in 2026<\/a>, so amycretin is still years from a possible approval, and it isn’t available through TrimRx or anywhere else outside of clinical trials.<\/p>\n Both use GLP-1 to curb appetite. Tirzepatide adds GIP, which appears to improve how the body handles fat and may ease nausea compared with GLP-1 alone. Amycretin adds amylin, a separate fullness hormone. These are different strategies, and there’s no head-to-head data between them, so any efficacy comparison is indirect.<\/p>\n This is the practical divide. Tirzepatide can be prescribed today. Amycretin is just entering Phase 3, so even in a best case it’s likely 2028 or later before approval. Choosing tirzepatide means starting now; “choosing” amycretin means waiting years for a drug that may or may not pan out.<\/p>\n Amycretin’s daily-pill option is its standout feature, and it’s something tirzepatide (injection-only) doesn’t offer. For people set on avoiding needles, that matters. But amycretin’s pill results trail its own injection, and the comparison is moot until amycretin is actually on the market.<\/p>\n On paper, amycretin’s early 22% and tirzepatide’s roughly 21% to 22.5% look similar, but the comparison is shaky: tirzepatide’s figure comes from a large, completed Phase 3 obesity trial, while amycretin’s comes from a small, early study. Tirzepatide has the proven, large-scale evidence. Amycretin’s numbers are encouraging but preliminary.<\/p>\n Amycretin is investigational and still in mid-stage development, so it can’t be prescribed, and there’s no legal compounded version (compounding applies to approved medications, which amycretin is not). Any “research-use-only” peptide sold online as amycretin sits outside pharmacy oversight, with no assurance of purity, sterility, or correct dosing, and isn’t a safe or legal substitute. The trial doses mentioned here reflect what researchers used under supervision, not a plan to follow yourself.<\/p>\n Tirzepatide is available now and is the most effective approved weight loss medication, so there’s a strong argument for starting it rather than waiting years for amycretin. The benefits accrue while you wait, not after, and the results tirzepatide can produce over a few months<\/a> are well documented. If amycretin or another drug proves better later, switching is straightforward.<\/p>\nWhat Is Amycretin?<\/h3>\n
Amycretin vs Tirzepatide at a Glance<\/h3>\n
\n\n
\n \nFeature<\/th>\n Amycretin<\/th>\n Tirzepatide (Zepbound\/Mounjaro)<\/th>\n<\/tr>\n<\/thead>\n \n Status<\/td>\n Investigational<\/td>\n FDA approved<\/td>\n<\/tr>\n \n Available now?<\/td>\n No<\/td>\n Yes<\/td>\n<\/tr>\n \n Mechanism<\/td>\n GLP-1 + amylin (one molecule)<\/td>\n GLP-1 + GIP<\/td>\n<\/tr>\n \n Form<\/td>\n Injectable and oral (in trials)<\/td>\n Weekly injection<\/td>\n<\/tr>\n \n Weight loss<\/td>\n ~22% at 36 weeks (early study)<\/td>\n ~21% to 22.5% (Phase 3)<\/td>\n<\/tr>\n \n Long-term data<\/td>\n Not yet<\/td>\n Yes<\/td>\n<\/tr>\n \n Earliest availability<\/td>\n ~2028 or later<\/td>\n Available today<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n The Key Differences<\/h3>\n
Different second hormones<\/h4>\n
Available versus years away<\/h4>\n
The pill question<\/h4>\n
What the data shows<\/h4>\n
Why Amycretin Isn’t Available Yet<\/h3>\n
What You Can Do Today<\/h3>\n